Duseja Ajay, De Arka, Singh Shivaram P, Madan Kaushal, Rao Padaki N, Shukla Akash, Choudhuri Gourdas, Saigal Sanjiv, Arora Anil, Anand Anil C, Das Ashim, Kumar Ashish, Eapen Chundamannil E, Devadas Krishnadas, Shenoy Kotacherry T, Panigrahi Manas, Wadhawan Manav, Rathi Manish, Choudhary Narendra S, Saraf Neeraj, Nath Preetam, Kar Sanjib, Alam Seema, Shah Samir, Nijhawan Sandeep, Acharya Subrat K, Aggarwal Vinayak, Saraswat Vivek A, Chawla Yogesh K
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Digestive Diseases Centre, Cuttack, India.
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102590. doi: 10.1016/j.jceh.2025.102590. Epub 2025 May 16.
The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive terminology, endorsed by over 70 international organisations including the Indian National Association for Study of the Liver (INASL), reduces stigma of 'fatty and alcohol' and allows the co-existence of other liver disease etiologies along with MASLD. In the present commentary, we discuss the implications of the adoption of new nomenclature of MASLD on the INASL guidance paper on NAFLD, which was published in 2023, before the Delphi consensus on MASLD.
从非酒精性脂肪性肝病（NAFLD）到代谢功能障碍相关脂肪性肝病（MASLD）的转变反映了肝病学领域的范式转变，强调代谢功能障碍是MASLD患者的核心驱动因素。这一包容性术语得到了包括印度国家肝脏研究协会（INASL）在内的70多个国际组织的认可，减少了“脂肪肝和酒精肝”的污名化，并允许MASLD与其他肝病病因共存。在本评论中，我们讨论了采用MASLD新命名法对INASL于2023年在关于MASLD的德尔菲共识之前发表的NAFLD指导文件的影响。
